DCF Tool

LFVN

Lifevantage Corporation – Pharmaceutical Preparation Manufacturing
LifeVantage Corporation is a pioneer in Nutrigenomics - a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQ™ weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.
Analysis Results
Intrinsic Value $11.28
Latest Price $3.75
Relative Value 67% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of -4.4%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 7.1%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of -4.4%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 9.47 8.85
2024 9.06 7.9
2025 8.66 7.06
2026 8.28 6.3
2027 7.92 5.63
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 160 million. This corresponds to a present value of 106 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 35.7 million. Adding in the terminal value gives a total present value of 142 million.

There are presently 12.6 million outstanding shares, so the intrinsic value per share is 11.28.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 46,957,000
Current Cash 20,190,000
Current Liabilities 25,728,000
Current Debt 0
Non-Cash Working Capital (NCWC) 1,039,000
Change in NCWC 1,358,000
EBIT 7,575,000
Tax Provision 1,571,000
Depreciation and Amortization 5,047,000
Capital Expenditure -1,530,000
Unlevered Free Cash Flow 9,913,158
Current Assets 48,054,000
Current Cash 23,174,000
Current Liabilities 25,199,000
Current Debt 0
Non-Cash Working Capital (NCWC) -319,000
Change in NCWC 2,970,000
EBIT 17,615,000
Tax Provision 4,338,000
Depreciation and Amortization 5,825,000
Capital Expenditure -3,741,000
Unlevered Free Cash Flow 18,234,583
Current Assets 43,868,000
Current Cash 22,138,000
Current Liabilities 25,019,000
Current Debt 0
Non-Cash Working Capital (NCWC) -3,289,000
Change in NCWC -2,912,000
EBIT 15,466,000
Tax Provision 3,112,000
Depreciation and Amortization 5,100,000
Capital Expenditure -2,681,000
Unlevered Free Cash Flow 11,690,127
Current Assets 43,188,000
Current Cash 18,824,000
Current Liabilities 26,195,000
Current Debt 1,454,000
Non-Cash Working Capital (NCWC) -377,000
Change in NCWC -858,000
EBIT 9,814,000
Tax Provision 1,801,000
Depreciation and Amortization 1,895,000
Capital Expenditure -2,506,000
Unlevered Free Cash Flow 6,430,047
Current Assets 38,938,000
Current Cash 16,652,000
Current Liabilities 23,805,000
Current Debt 2,000,000
Non-Cash Working Capital (NCWC) 481,000
Change in NCWC -2,252,000
EBIT 10,323,000
Tax Provision 3,787,000
Depreciation and Amortization 1,325,000
Capital Expenditure -4,649,000
Unlevered Free Cash Flow 652,613
Current Assets 35,546,000
Current Cash 11,458,000
Current Liabilities 23,355,000
Current Debt 2,000,000
Non-Cash Working Capital (NCWC) 2,733,000
Change in NCWC -5,243,000
EBIT 4,449,000
Tax Provision 1,302,000
Depreciation and Amortization 1,643,000
Capital Expenditure -1,055,000
Unlevered Free Cash Flow -2,196,583
Current Assets 42,409,000
Current Cash 7,883,000
Current Liabilities 28,550,000
Current Debt 2,000,000
Non-Cash Working Capital (NCWC) 7,976,000
Change in NCWC 6,125,000
EBIT 13,414,000
Tax Provision 2,665,000
Depreciation and Amortization 1,895,000
Capital Expenditure -562,000
Unlevered Free Cash Flow 16,755,428
Current Assets 30,475,000
Current Cash 13,905,000
Current Liabilities 25,860,000
Current Debt 11,141,000
Non-Cash Working Capital (NCWC) 1,851,000
Change in NCWC 267,000
EBIT 13,899,000
Tax Provision 3,666,000
Depreciation and Amortization 2,285,000
Capital Expenditure -1,159,000
Unlevered Free Cash Flow 10,508,959
Current Assets 39,973,000
Current Cash 20,387,000
Current Liabilities 22,702,000
Current Debt 4,700,000
Non-Cash Working Capital (NCWC) 1,584,000
Change in NCWC 2,508,000
EBIT 19,448,000
Tax Provision 5,272,000
Depreciation and Amortization 2,118,000
Capital Expenditure -2,248,000
Unlevered Free Cash Flow 15,669,899
Current Assets 45,941,000
Current Cash 26,299,000
Current Liabilities 20,566,000
Current Debt 0
Non-Cash Working Capital (NCWC) -924,000
Change in NCWC 923,400
EBIT 12,068,000
Tax Provision 3,545,000
Depreciation and Amortization 1,659,000
Capital Expenditure -5,080,000
Unlevered Free Cash Flow 5,734,565
Current Assets 38,827,967
Current Cash 24,647,585
Current Liabilities 16,027,782
Current Debt 0
Non-Cash Working Capital (NCWC) -1,847,400
Change in NCWC 7,544,635
EBIT 21,456,384
Tax Provision 2,202,548
Depreciation and Amortization 521,271
Capital Expenditure -2,246,272
Unlevered Free Cash Flow 24,054,921

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.